Literature DB >> 8909606

Comparison of measures of exposure to asbestos in former crocidolite workers from Wittenoom Gorge, W. Australia.

N H de Klerk1, A W Musk, V Williams, P R Filion, D Whitaker, K B Shilkin.   

Abstract

Determinations of exposure-response relationships between crocidolite and the major asbestos-related diseases in the Wittenoom cohort have previously depended on the validity of estimates of airborne exposure to asbestos. This work aims to validate the airborne exposure measurements by obtaining measurements of the concentrations of uncoated crocidolite fibers and asbestos bodies retained in the lungs of individual workers, and to estimate the half-life of crocidolite fibers in the lungs. Samples of lung tissue, excluding tumor, of all former Wittenoom workers known to have died in Western Australia (WA) were sought from teaching hospitals, pathology departments, and the Coroner's pathologist. The lung specimens were processed using Pooley's method with TEM for counts of fibers of all types and using Smith and Naylor's method with conventional light microscopy for asbestos bodies (AB). Multiple linear regression was utilized to examine the associations between crocidolite concentrations in the lung and duration of employment at Wittenoom, time since last employed at Wittenoom, nature of job, estimated average fiber concentration at the worksite, and estimated cumulative crocidolite exposure (CCE) in fiber-years/ml for each subject. Lung tissue from 90 cases was processed and there was good agreement between counts of crocidolite fibers, asbestos bodies, and CCE. Correlations were 0.77 for AB and fibers, 0.54 for AB and CCE, and 0.58 for CCE and fibers, after log transformation. The half-life of crocidolite fibers in the lung was estimated at 92 months (95% CI 55-277 months). Previous estimates of airborne exposure to Wittenoom crocidolite have been reasonably reliable. The relatively simple technique of light microscopy for counting ABs in lung tissue also provides a useful and reliable indication of the level of past occupational exposure to crocidolite in subjects whose exposure has been only to crocidolite. The half-life of crocidolite fibers in the lungs of former Wittenoom workers is about 7-8 years.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8909606     DOI: 10.1002/(SICI)1097-0274(199611)30:5<579::AID-AJIM5>3.0.CO;2-O

Source DB:  PubMed          Journal:  Am J Ind Med        ISSN: 0271-3586            Impact factor:   2.214


  11 in total

1.  The effect of asbestosis on lung cancer risk beyond the dose related effect of asbestos alone.

Authors:  A Reid; N de Klerk; G L Ambrosini; N Olsen; S C Pang; G Berry; A W Musk
Journal:  Occup Environ Med       Date:  2005-12       Impact factor: 4.402

Review 2.  Mesothelioma: cases associated with non-occupational and low dose exposures.

Authors:  G Hillerdal
Journal:  Occup Environ Med       Date:  1999-08       Impact factor: 4.402

3.  The additional risk of malignant mesothelioma in former workers and residents of Wittenoom with benign pleural disease or asbestosis.

Authors:  A Reid; N de Klerk; G Ambrosini; N Olsen; S C Pang; A W Musk
Journal:  Occup Environ Med       Date:  2005-10       Impact factor: 4.402

4.  Prediction of mesothelioma and lung cancer in a cohort of asbestos exposed workers.

Authors:  Antonio Gasparrini; Anna Maria Pizzo; Giuseppe Gorini; Adele Seniori Costantini; Stefano Silvestri; Cesare Ciapini; Andrea Innocenti; Geoffrey Berry
Journal:  Eur J Epidemiol       Date:  2008-04-26       Impact factor: 8.082

Review 5.  Applying definitions of "asbestos" to environmental and "low-dose" exposure levels and health effects, particularly malignant mesothelioma.

Authors:  B W Case; J L Abraham; G Meeker; F D Pooley; K E Pinkerton
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2011       Impact factor: 6.393

6.  Malignant mesotheliomas in former miners and millers of crocidolite at Wittenoom (Western Australia) after more than 50 years follow-up.

Authors:  G Berry; A Reid; P Aboagye-Sarfo; N H de Klerk; N J Olsen; E Merler; P Franklin; A W Musk
Journal:  Br J Cancer       Date:  2012-02-07       Impact factor: 7.640

7.  Pleural mesothelioma and lung cancer risks in relation to occupational history and asbestos lung burden.

Authors:  Clare Gilham; Christine Rake; Garry Burdett; Andrew G Nicholson; Leslie Davison; Angelo Franchini; James Carpenter; John Hodgson; Andrew Darnton; Julian Peto
Journal:  Occup Environ Med       Date:  2015-12-29       Impact factor: 4.402

8.  The asbestos fibre burden in human lungs: new insights into the chrysotile debate.

Authors:  Inke Sabine Feder; Iris Tischoff; Anja Theile; Inge Schmitz; Rolf Merget; Andrea Tannapfel
Journal:  Eur Respir J       Date:  2017-06-29       Impact factor: 16.671

9.  Cumulative asbestos exposure and mortality from asbestos related diseases in a pooled analysis of 21 asbestos cement cohorts in Italy.

Authors:  Ferdinando Luberto; Daniela Ferrante; Stefano Silvestri; Alessia Angelini; Francesco Cuccaro; Anna Maria Nannavecchia; Enrico Oddone; Massimo Vicentini; Francesco Barone-Adesi; Tiziana Cena; Dario Mirabelli; Lucia Mangone; Francesca Roncaglia; Orietta Sala; Simona Menegozzo; Roberta Pirastu; Danila Azzolina; Sara Tunesi; Elisabetta Chellini; Lucia Miligi; Patrizia Perticaroli; Aldo Pettinari; Vittoria Bressan; Enzo Merler; Paolo Girardi; Lucia Bisceglia; Alessandro Marinaccio; Stefania Massari; Corrado Magnani
Journal:  Environ Health       Date:  2019-08-07       Impact factor: 5.984

10.  Consensus Report of the 2015 Weinman International Conference on Mesothelioma.

Authors:  Michele Carbone; Shreya Kanodia; Ann Chao; Aubrey Miller; Anil Wali; David Weissman; Alex Adjei; Francine Baumann; Paolo Boffetta; Brenda Buck; Marc de Perrot; A Umran Dogan; Steve Gavett; Alessandro Gualtieri; Raffit Hassan; Mary Hesdorffer; Fred R Hirsch; David Larson; Weimin Mao; Scott Masten; Harvey I Pass; Julian Peto; Enrico Pira; Ian Steele; Anne Tsao; Gavitt Alida Woodard; Haining Yang; Shakun Malik
Journal:  J Thorac Oncol       Date:  2016-08       Impact factor: 15.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.